



COVID-19 Vaccination Billing Resources for Local Health Departments

January 25, 2022

Table of Contents

Cost.....	2
Coding.....	2
Pfizer-BioNTech COVID-19 Vaccine (Ages 12 & up).....	2
Pfizer-BioNTech COVID-19 Vaccine (Ready to Use: ages 12 & up).....	2
Pfizer-BioNTech COVID-19 Vaccine (Ages 5 to 11).....	2
Moderna COVID-19 Vaccine	3
Janssen COVID-19 Vaccine.....	3
Billing.....	4
Summary of COVID-19 Vaccination Coding for Local Health Departments.....	5
NC Medicaid, Medicare & HRSA COVID-19 Vaccination Billing Guidance.....	7
Recently Released NC Medicaid COVID-19 Special Bulletins.....	8
SPECIAL BULLETIN COVID-19 #210: NC Medicaid Omicron COVID-19 Surge.....	8
SPECIAL BULLETIN COVID-19 #217: Third Dose of Pfizer-BioNTech Vaccine for Children Ages 5-11.....	8
Resources.....	9
Medicare	10
HRSA Portal	10
NC DHHS COVID-19 Response – Information for Healthcare Providers	10

Cost

How much will the vaccines cost?

There is no cost. They are free to everyone, even if you do not have health insurance. The federal government is covering the cost.

Source: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/no-cost.html>

“All providers must vaccinate individuals regardless of whether they have health insurance coverage or what type of coverage they have and are prohibited from balance billing or otherwise charging vaccine recipients.”

Source: <https://www.medicaid.gov/state-resource-center/downloads/covid-19-vaccine-toolkit.pdf>

Coding

The American Medical Association (AMA) published an update to the Current Procedural Terminology (CPT®) code set that includes new vaccine-specific codes to report immunizations for the novel coronavirus (SARS-CoV-2, COVID-19).

This level of specificity offers the ability to track each vaccine dose, even when the vaccine product is not reported (e.g., when the vaccine may be given to the patient for free). These CPT codes report the actual work of administering the vaccine, in addition to all necessary counseling provided to patients or caregivers and updating the electronic record.

Pfizer-BioNTech COVID-19 Vaccine (Ages 12 & up)

91300: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use.

0001A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; **first dose**.

0002A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; **second dose**.

0003A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; **third dose**.

0004A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; **booster dose**.

Pfizer-BioNTech COVID-19 Vaccine (Ready to Use: ages 12 & up)

91305: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use

0051A: Pfizer-BioNTech Covid-19 Vaccine (Ready to Use) Administration - **first dose**.

0052A: Pfizer-BioNTech Covid-19 Vaccine (Ready to Use) Administration - **second dose**.

0053A: Pfizer-BioNTech Covid-19 Vaccine (Ready to Use) Administration - **third dose**.

0054A: Pfizer-BioNTech COVID-19 Vaccine (Ready to Use) Administration - **booster**.

Pfizer-BioNTech COVID-19 Vaccine (Ages 5 to 11)

91307: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use

0071A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; **first dose**.

0072A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; **second dose**.

0073A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; **third dose**.

Moderna COVID-19 Vaccine

91301: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use.

0011A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; **first dose**.

0012A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; **second dose**.

0013A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; **third dose**.

Moderna COVID-19 Booster

91306: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use, **booster vaccine**.

0064A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, **booster dose**.

Janssen COVID-19 Vaccine

91303: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10¹⁰ viral particles/0.5mL dosage, for intramuscular use.

0031A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10¹⁰ viral particles/0.5mL dosage, **single dose**.

0034A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10¹⁰ viral particles/0.5 mL dosage; **booster dose**.

Source: American Medical Association

<https://www.ama-assn.org/system/files/2020-11/covid-19-immunizations-appendix-q-table.pdf>

<https://www.ama-assn.org/press-center/press-releases/ama-announces-update-covid-19-vaccine-cpt-codes>

<https://www.ama-assn.org/practice-management/cpt/new-cpt-codes-coronavirus-vaccines-what-you-need-know>

<https://www.ama-assn.org/press-center/press-releases/ama-announces-update-covid-19-vaccine-cpt-codes-2>

<https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codes>

Billing

“Vaccine doses purchased with U.S. taxpayer dollars will be given to the American people at no cost. However, vaccination providers may be able to charge administration fees for giving the shot. Vaccination providers can get this fee reimbursed by the patient’s public or private insurance company or, for uninsured patients, by the Health Resources and Services Administration’s Provider Relief Fund (HRSA).”

Source: CDC, <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/8-things.html>

It is recommended to review your private insurance’s resources for specific billing guidance pertinent to that insurance.

Make sure you enter the CPT Codes for the vaccine and the administration fee into your billing system and the COVID-19 Vaccine Management System (CVMS).

The below table provides a summary of the billing codes for the payers specified in this document. For additional details, please refer to the resources of this document.

Summary of COVID-19 Vaccination Coding for Local Health Departments				
	Payers	CPT Codes	National Drug Classification	Details
Pfizer	NC Medicaid; Medicare; HRSA	Ages 12 & up 91300 – Pfizer COVID-19 vaccine 0001A – Admin of Pfizer COVID-19 vaccine, 1 st dose 0002A – Admin of Pfizer COVID-19 vaccine, 2 nd dose 0003A – Admin of Pfizer COVID-19 vaccine, 3 rd dose 0004A – Admin of Pfizer COVID-19 vaccine, booster	59267-1000-01 59267-1000-02 59267-1000-03	No reimbursement for the actual COVID-19 vaccine Effective 03/15/2021 reimbursement provided by Medicare and HRSA for each administration of the COVID-19 vaccine is \$40.00. Per the January 7, 2022, NC Medicaid Special Bulletin COVID-19 #210 , NC Medicaid will be reimbursing \$65.00 for the administration of the COVID-19 vaccine with an retroactive date of reimbursement to April 1, 2021.
	NC Medicaid; Medicare; HRSA*	Ready to Use: Ages 12 & up 91305 – Pfizer COVID-19 vaccine 0051A – (Ready to Use) Admin of Pfizer COVID-19 vaccine, 1 st dose 0052A – (Ready to Use) Admin of Pfizer COVID-19 vaccine, 2 nd dose 0053A – (Ready to Use) Admin of Pfizer COVID-19 vaccine, 3 rd dose 0054A – (Ready to Use) Admin of Pfizer COVID-19 vaccine, booster	59267-1025-01 59267-1025-02 59267-1025-03 59267-1025-04	
	NC Medicaid; Medicare; HRSA*	Ages 5 to 11 91307 – Pfizer COVID-19 vaccine, pediatric 0071A – Admin of Pfizer COVID-19 vaccine, 1 st dose 0072A – Admin of Pfizer COVID-19 vaccine, 2 nd dose 0073A – Admin of Pfizer COVID-19 vaccine, 3 rd dose*	59267-1055-01 59267-1055-02 59267-1055-04	
Moderna	NC Medicaid; Medicare; HRSA	91301 – Moderna COVID-19 vaccine 0011A – Admin of Moderna COVID-19 vaccine, 1 st dose 0012A – Admin of Moderna COVID-19 vaccine, 2 nd dose 0013A – Admin of Moderna COVID-19 vaccine, 3 rd dose	80777-0273-10 80777-0273-99 80777-0273-15 80777-0273-98	
	NC Medicaid; Medicare; HRSA	91306 – Moderna COVID-19 vaccine, booster 0064A – Admin of Moderna COVID-19 vaccine, booster dose	80777-0273-10	
Janssen	NC Medicaid; Medicare; HRSA	91303 – Janssen COVID-19 vaccine 0031A – Admin of Janssen COVID-19 vaccine 0034A – Admin of Janssen COVID-19 vaccine, booster	59676-0580-15	
	NC Medicaid	99401 – Preventative medicine counseling and/or risk factor reduction intervention (s) provided to an individual, up to 15 minutes	N/A	Effective 06/22/2021 reimbursement of provider vaccine counseling is \$32.94.
	Medicare	M0201 - Additional payment for administering the COVID-19 vaccine to certain Medicare patients in their homes	N/A	Effective 06/08/2021 reimbursement of additional payment for administering COVID-19 vaccine to certain

				patients in their homes of \$35.00.
*At the time of this document, HRSA has not added newly listed codes for reimbursement.				
Resources: COVID-19 Special Medicaid Bulletins, https://medicaid.ncdhhs.gov/about-us/covid-19-guidance-and-resources/providers/covid-19-special-medicaid-bulletins Medicare Billing for COVID-19 Vaccine Shot Administration, https://www.cms.gov/medicare/covid-19/medicare-billing-covid-19-vaccine-shot-administration HRSA, COVID-19 Claims Reimbursement, https://coviduninsuredclaim.linkhealth.com/billing-codes.html				

NC Medicaid, Medicare & HRSA COVID-19 Vaccination Billing Guidance

NC Medicaid & NCHC	Medicare	HRSA
<ul style="list-style-type: none"> The ICD-10-CM diagnosis code required for billing is: Z23 - Encounter for immunization Providers must bill 11-digit NDCs <ul style="list-style-type: none"> The NDC units should be reported as "UN1" Pfizer BioNTech COVID-19 Vaccine 0.3mL = 1 unit Pfizer BioNTech COVID-19 Vaccine 0.2mL (pediatric) = 1 unit Moderna COVID-19 Vaccine 0.5mL = 1 unit Moderna COVID-19 Vaccine Booster 0.25mL = 1 unit Janssen COVID-19 Vaccine 0.5mL = 1 unit Claims must contain both administration codes and vaccine codes to pay. Vaccine codes should be reported as \$0.00. Claims for first vaccine dose must have been processed, prior to processing a claim for second dose. Modifiers <ul style="list-style-type: none"> TJ modifier should be used for NC Health Choice claims (age 6 through 18 years). EP modifier should be used for all non-NC Health Choice (only Medicaid beneficiaries) younger than 21 years of age. Visit Medicaid's website for these guidelines: https://medicaid.ncdhhs.gov/providers/medicaid-bulletin 	<ul style="list-style-type: none"> You'll be able to bill on single claims for COVID-19 shot administration or submit claims on a roster bill for multiple patients at one time. When COVID-19 vaccine doses are provided by the government without charge, only bill for the vaccine administration. Don't include the vaccine codes on the claim when the vaccines are free. If you participate in a Medicare Advantage Plan, submit your COVID-19 claims to Original Medicare for all patients enrolled in Medicare Advantage in 2020 and 2021. <p>Administration of COVID-19 Vaccine to Certain Medicare Patients in their Homes Effective June 8, 2021, CMS has announced the use of HCPCS Level II code M0201 for the additional payment for administering the COVID-19 vaccine to certain Medicare patients in their homes.</p> <ul style="list-style-type: none"> You should report this code in addition to the appropriate CPT code for the product- and dose-specific COVID-19 vaccine administration You can only report the HCPCS Level II code for home vaccine administration once per home per date of service If you administer the COVID-19 vaccine to more than 1 Medicare patient in a single home on the same day, you should: <ul style="list-style-type: none"> Only report the HCPCS Level II code M0201 once Report the appropriate CPT code for the product- and dose-specific COVID-19 vaccine administration for each Medicare patient vaccinated in the home that day 	<p>Claims submitted for the administration of an FDA-licensed or authorized vaccine must be submitted as single line item claims, and must include one of the following codes to be eligible for reimbursement:</p> <ul style="list-style-type: none"> Pfizer: 0001A, 0002A, 0003A, 0004A, 0071A, 0072A Moderna: 0011A, 0012A, 00013A, 0064A Janssen: 0031A, 0034A <p>Please note that only the administration of the vaccine is eligible for reimbursement through the HRSA COVID-19 Uninsured Program.</p> <p>Visit HRSA's Uninsured Program website for these guidelines: https://coviduninsuredclaim.linkhealth.com/</p> <p><i>*At the time of this document, HRSA has not added newly listed codes for reimbursement.</i></p>

Evaluation by Provider related to COVID-19 Vaccination

A provider that consults a patient, either in-person or telemedicine, for the purpose of evaluation of history and/or examination/assessment for receiving the COVID-19 vaccination may code and bill the appropriate evaluation and management service code for services rendered. The record of these visits must meet documentation standards required for reimbursement of services.

Recently Released NC Medicaid COVID-19 Special Bulletins

[SPECIAL BULLETIN COVID-19 #203: NC Medicaid Revising and/or End-Dating All Temporary COVID-19 Rate Increases](#)

Effective Dec. 31, 2021, NC Medicaid will end several of the temporary COVID-19 rate increases. Some of the rate increases in effect in December 2021 will be extended – at either current or revised levels - through Jan. 31, 2022. The temporary 5% COVID-19 rate increase associated with Session Law 2020-4 (House Bill 1043) will be end-dated as of Dec. 31, 2021 for all NC Medicaid Direct (formerly known as fee-for-service) programs that are not classified as Home- and Community-Based (HCBS) services, as defined in Section 9817 of the American Rescue Plan. This also includes end-dating any increases above the GA 5% rate increase for Local Health Departments.

[SPECIAL BULLETIN COVID-19 #210: NC Medicaid Omicron COVID-19 Surge COVID-19 Vaccine Counseling](#)

NC Medicaid remains committed to creating opportunities for beneficiaries to receive the COVID-19 vaccine and for providers to assist in overcoming misinformation and vaccine hesitancy. To that end, we continue to reimburse for the COVID-19 vaccine counseling code, 99401, as well as outreach. Please refer to [Special Bulletin COVID-19 #192: Vaccination Outreach Code Reimbursement](#) for more details. Because this code is being used for the unique purpose of COVID-19 vaccine counseling with the modifier CR, original CPT code limitations such as nights and weekends do not apply for the express use of this code for COVID-19 vaccine counseling.

Please follow the below guidance on modifiers to use with 99401:

- Requires CR if provided in person
- Requires CR and GT modifiers if provided via telehealth
- Requires CR and KX modifiers if provided telephonically
- Requires CR and HM modifiers if provided by office staff phoning unvaccinated members on their patient list.

[COVID-19 Vaccine Administration Reimbursement](#)

NC Medicaid is increasing the reimbursement for COVID vaccine administration from \$40 to \$65. The effective date of the rate change will be retroactive to April 1, 2021. All claims previously submitted with dates of service from April 1, 2021 through the NCTracks implementation date of the rate change will be systematically reprocessed. No action will be required by providers to receive the retroactive rate increase.

[SPECIAL BULLETIN COVID-19 #217: Third Dose of Pfizer-BioNTech Vaccine for Children Ages 5-11](#)

On Jan. 3, 2022, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine to allow for a third dose in the primary series for certain immunocompromised children ages 5 through 11. This includes children who have undergone solid organ transplantation or who have been diagnosed with conditions which are considered to have an equivalent level of immunocompromise. Children ages 5 through 11 who are fully vaccinated and are not immunocompromised do not need a third dose at this time.

As of Jan. 3, 2022, Medicaid and NC Health Choice will cover a third dose of the Pfizer-BioNTech COVID-19 Vaccine primary series for immunocompromised children ages 5 through 11 for all vaccinating providers.

Resources

NC Medicaid

[SPECIAL BULLETIN COVID-19 #147: Moderna COVID-19 Vaccine \(N/A\) HCPCS code 91301: Billing Guidelines](#)

[SPECIAL BULLETIN COVID-19 #148: Pfizer-BioNTech COVID-19 Vaccine \(N/A\) HCPCS Code 91300: Billing Guidelines](#)

[SPECIAL BULLETIN COVID-19 #160: Janssen COVID-19 Vaccine HCPCS Code 91303 and 0031A Billing Guidelines](#)

[SPECIAL BULLETIN COVID-19 #162: Medicaid Rate Increases for COVID-19 Vaccine Administration Codes](#)

[SPECIAL BULLETIN COVID-19 #163: Temporary Provider Rate Increases and Clinical Policy Changes Extended](#)

[SPECIAL BULLETIN COVID-19 #165: Update to Approved Vaccines Covered by NC Medicaid](#)

[SPECIAL BULLETIN COVID-19 #168: Vaccination Counseling Code Reimbursement](#)

[SPECIAL BULLETIN COVID-19 #169: Temporary Provider Rate Increases and Clinical Policy Changes Extended](#)

[SPECIAL BULLETIN COVID-19 #170: Update on Vaccination Counseling Code Reimbursement](#)

[SPECIAL BULLETIN COVID-19 #171: COVID-19 Rate Increases Under NC Medicaid Managed Care](#)

[SPECIAL BULLETIN COVID-19 #174: Temporary Provider Rate Increases and Clinical Policy Changes Extended](#)

[SPECIAL BULLETIN COVID-19 #176: Third COVID-19 Vaccine Available](#)

[SPECIAL BULLETIN COVID-19 #179: Temporary Provider Rate Increases and Clinical Policy Changes Extended](#)

[SPECIAL BULLETIN COVID-19 #184: Update on Vaccination Counseling Code Reimbursement](#)

[SPECIAL BULLETIN COVID-19 #186: Booster Dose of Pfizer-BioNTech COVID-19 Vaccine](#)

[SPECIAL BULLETIN COVID-19 #192: Vaccination Outreach Code Reimbursement](#)

[SPECIAL BULLETIN COVID-19 #193: Public Health Emergency Extended](#)

[SPECIAL BULLETIN COVID-19 #195: Booster Dose of Pfizer, Moderna and Janssen Vaccines](#)

[SPECIAL BULLETIN COVID-19 #196: Pfizer Pediatric Vaccine Authorized](#)

[SPECIAL BULLETIN COVID-19 #198: Pfizer Vaccine for 12 Years and Older](#)

[SPECIAL BULLETIN COVID-19 #199: Temporary Provider Rate Increases and Clinical Policy Changes Extended](#)

[SPECIAL BULLETIN COVID-19 #201: Booster Dose of COVID-19 Vaccines for All Adults](#)

[SPECIAL BULLETIN COVID-19 #203: NC Medicaid Revising and/or End-Dating All Temporary COVID-19 Rate Increases](#)

[SPECIAL BULLETIN COVID-19 #205: Change in Age for Pfizer-BioNTech COVID-19 Booster Vaccine](#)

[SPECIAL BULLETIN COVID-19 #206: Coverage for COVID-19 Treatment for NC Medicaid Optional Eligibility Group](#)

[SPECIAL BULLETIN COVID-19 #208: Amended Outpatient Billing Guidance for Vaccine and Monoclonal Antibody Administration](#)

[SPECIAL BULLETIN COVID-19 #210: NC Medicaid Omicron COVID-19 Surge](#)

[SPECIAL BULLETIN COVID-19 #211: Pfizer-BioNTech Booster Dose: Minimum Age Change; Permission to Administer Five Months Post-Second Dose](#)

[SPECIAL BULLETIN COVID-19 #217: Third Dose of Pfizer-BioN Tech Vaccine for Children Ages 5-11](#)

Medicare

[Medicare COVID-19 Vaccine Shot Payment](#)

[Medicare Billing COVID-19 Vaccine Shot Administration](#)

HRSA Portal

[HRSA COVID-19 Claims Reimbursement Portal](#)

NC DHHS COVID-19 Response – Information for Healthcare Providers

<https://covid19.ncdhhs.gov/vaccines/providers>